Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Создавая историю на страницах книги диффузной В-крупноклеточной лимфомы. Объединенный VI Конгресс гематологов России и III Конгресс трансфузиологов. Обзор симпозиума 21 апреля 2022 г., Москва
Создавая историю на страницах книги диффузной В-крупноклеточной лимфомы. Объединенный VI Конгресс гематологов России и III Конгресс трансфузиологов. Обзор симпозиума 21 апреля 2022 г., Москва
Создавая историю на страницах книги диффузной В-крупноклеточной лимфомы. Современная Онкология. 2022;24(2):150–157. DOI: 10.26442/18151434.2022.2.201711
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В рамках Объединенного VI Конгресса гематологов России и III Конгресса трансфузиологов России 21 апреля состоялся симпозиум, посвященный диффузной В-крупноклеточной лимфоме (ДВКЛ). Ведущие российские эксперты обсудили современные тенденции в диагностике, причины неудач и успехов терапии этого гетерогенного заболевания, изменения, которые ожидаются в самое ближайшее время. Во время симпозиума были представлены подробные данные о новой опции терапии ДВКЛ – иммуноконъюгате полатузумабе ведотине. Симпозиум проведен при поддержке компании «Рош».
Ключевые слова: диффузная В-крупноклеточная лимфома, химиотерапия, иммунотерапия, таргетная терапия, иммуноконъюгаты, полатузумаб ведотин, исследование POLARIX, исследование GO29365
Keywords: diffuse large B cell lymphoma, chemotherapy, immunotherapy, targeted therapy, immunoconjugates, polatuzumab vedotin, the POLARIX trial, the GO29365 trial
Ключевые слова: диффузная В-крупноклеточная лимфома, химиотерапия, иммунотерапия, таргетная терапия, иммуноконъюгаты, полатузумаб ведотин, исследование POLARIX, исследование GO29365
________________________________________________
Keywords: diffuse large B cell lymphoma, chemotherapy, immunotherapy, targeted therapy, immunoconjugates, polatuzumab vedotin, the POLARIX trial, the GO29365 trial
Полный текст
Список литературы
1. Cancer death rates are falling; five-year survival rates are rising. Available: https://ourworldindata.org/cancer-death-rates-are-falling-five-year-survival-rates-are-rising/ Accessed: 18.04.2022.
2. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-407. DOI:10.1056/NEJMoa1801445
3. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-90. DOI:10.1038/s41591-018-0016-8
4. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551-68.e14. DOI:10.1016/j.ccell.2020.03.015
5. Feugier P, Hoof AV, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-26. DOI:10.1200/JCO.2005.09.131
6. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. DOI:10.1182/blood-2017-03-769620
7. Клинические рекомендации по лечению агрессивных нефолликулярных лимфом. Проект 2021–2022. Режим доступа: https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Ссылка активна на 18.04.2022 [Klinicheskie rekomendatsii po lecheniiu agressivnykh nefollikuliarnykh lim-fom. Proekt 2021–2022. Available:https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Accessed: 18.04.2022 (in Russian)].
8. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-15. DOI:10.1016/S1470-2045(15)70128-2
9. Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721-9. DOI:10.1182/blood-2009-02-205500
10. Polson A, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Invest Drug. 2011;20:75-85. DOI:10.1517/13543784.2011.539557
11. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458‑65. DOI:10.1182/blood-2003-01-0039
12. Beck A, Lambert J, Sun M, et al. Fourth World Antibody-Drug Conjugate Summit: February 29 – March 1, 2012, Frankfurt, Germany. MAbs. 2012;4(6):637‑47. DOI:10.4161/mabs.21697
13. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-65. DOI:10.1200/JCO.19.00172
14. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-43. DOI:10.1182/bloodadvances.2021005794
15. Zhang M, Xu P, Wang L, et al. Genetic Subtype Guided Rituximab-Based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-Cell Lymphoma: First Report of a Randomized Phase 2 Study. Hematol Oncol. 2021;39(Suppl. 2). DOI:10.1002/hon.26_2879
16. Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735-42. DOI:10.1038/s41591-022-01731-4
17. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-63. DOI:10.1056/NEJMoa2115304
2. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-407. DOI:10.1056/NEJMoa1801445
3. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-90. DOI:10.1038/s41591-018-0016-8
4. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551-68.e14. DOI:10.1016/j.ccell.2020.03.015
5. Feugier P, Hoof AV, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-26. DOI:10.1200/JCO.2005.09.131
6. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. DOI:10.1182/blood-2017-03-769620
7. Klinicheskie rekomendatsii po lecheniiu agressivnykh nefollikuliarnykh lim-fom. Proekt 2021–2022. Available:https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Accessed: 18.04.2022 (in Russian).
8. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-15. DOI:10.1016/S1470-2045(15)70128-2
9. Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721-9. DOI:10.1182/blood-2009-02-205500
10. Polson A, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Invest Drug. 2011;20:75-85. DOI:10.1517/13543784.2011.539557
11. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458‑65. DOI:10.1182/blood-2003-01-0039
12. Beck A, Lambert J, Sun M, et al. Fourth World Antibody-Drug Conjugate Summit: February 29 – March 1, 2012, Frankfurt, Germany. MAbs. 2012;4(6):637‑47. DOI:10.4161/mabs.21697
13. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-65. DOI:10.1200/JCO.19.00172
14. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-43. DOI:10.1182/bloodadvances.2021005794
15. Zhang M, Xu P, Wang L, et al. Genetic Subtype Guided Rituximab-Based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-Cell Lymphoma: First Report of a Randomized Phase 2 Study. Hematol Oncol. 2021;39(Suppl. 2). DOI:10.1002/hon.26_2879
16. Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735-42. DOI:10.1038/s41591-022-01731-4
17. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-63. DOI:10.1056/NEJMoa2115304
2. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-407. DOI:10.1056/NEJMoa1801445
3. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-90. DOI:10.1038/s41591-018-0016-8
4. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551-68.e14. DOI:10.1016/j.ccell.2020.03.015
5. Feugier P, Hoof AV, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-26. DOI:10.1200/JCO.2005.09.131
6. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. DOI:10.1182/blood-2017-03-769620
7. Клинические рекомендации по лечению агрессивных нефолликулярных лимфом. Проект 2021–2022. Режим доступа: https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Ссылка активна на 18.04.2022 [Klinicheskie rekomendatsii po lecheniiu agressivnykh nefollikuliarnykh lim-fom. Proekt 2021–2022. Available:https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Accessed: 18.04.2022 (in Russian)].
8. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-15. DOI:10.1016/S1470-2045(15)70128-2
9. Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721-9. DOI:10.1182/blood-2009-02-205500
10. Polson A, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Invest Drug. 2011;20:75-85. DOI:10.1517/13543784.2011.539557
11. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458‑65. DOI:10.1182/blood-2003-01-0039
12. Beck A, Lambert J, Sun M, et al. Fourth World Antibody-Drug Conjugate Summit: February 29 – March 1, 2012, Frankfurt, Germany. MAbs. 2012;4(6):637‑47. DOI:10.4161/mabs.21697
13. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-65. DOI:10.1200/JCO.19.00172
14. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-43. DOI:10.1182/bloodadvances.2021005794
15. Zhang M, Xu P, Wang L, et al. Genetic Subtype Guided Rituximab-Based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-Cell Lymphoma: First Report of a Randomized Phase 2 Study. Hematol Oncol. 2021;39(Suppl. 2). DOI:10.1002/hon.26_2879
16. Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735-42. DOI:10.1038/s41591-022-01731-4
17. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-63. DOI:10.1056/NEJMoa2115304
________________________________________________
2. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-407. DOI:10.1056/NEJMoa1801445
3. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-90. DOI:10.1038/s41591-018-0016-8
4. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551-68.e14. DOI:10.1016/j.ccell.2020.03.015
5. Feugier P, Hoof AV, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-26. DOI:10.1200/JCO.2005.09.131
6. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. DOI:10.1182/blood-2017-03-769620
7. Klinicheskie rekomendatsii po lecheniiu agressivnykh nefollikuliarnykh lim-fom. Proekt 2021–2022. Available:https://rusoncohem.ru/klinrec/agressivnye nefollikulyarnye limfomy proekt 2021 2022/#_ Toc96601232/ Accessed: 18.04.2022 (in Russian).
8. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-15. DOI:10.1016/S1470-2045(15)70128-2
9. Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721-9. DOI:10.1182/blood-2009-02-205500
10. Polson A, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Invest Drug. 2011;20:75-85. DOI:10.1517/13543784.2011.539557
11. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458‑65. DOI:10.1182/blood-2003-01-0039
12. Beck A, Lambert J, Sun M, et al. Fourth World Antibody-Drug Conjugate Summit: February 29 – March 1, 2012, Frankfurt, Germany. MAbs. 2012;4(6):637‑47. DOI:10.4161/mabs.21697
13. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-65. DOI:10.1200/JCO.19.00172
14. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-43. DOI:10.1182/bloodadvances.2021005794
15. Zhang M, Xu P, Wang L, et al. Genetic Subtype Guided Rituximab-Based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-Cell Lymphoma: First Report of a Randomized Phase 2 Study. Hematol Oncol. 2021;39(Suppl. 2). DOI:10.1002/hon.26_2879
16. Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735-42. DOI:10.1038/s41591-022-01731-4
17. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-63. DOI:10.1056/NEJMoa2115304
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.